Alvotech (NASDAQ:ALVO) is one of the most promising penny stocks according to Wall Street analysts. On May 11, Alvotech announced the completion of a routine FDA surveillance inspection at its manufacturing facility in Reykjavik, Iceland. While the FDA issued a Form 483 at the conclusion of the visit on May 8, 2026, the company stated that it believes the observations are manageable and do not indicate significant issues with the site’s overall operations or compliance.
Management views the results as a validation of the facility’s current cGMP fundamentals and the effectiveness of improvements implemented over the past year. Consequently, the company remains on schedule to resubmit its relevant BLAs during Q2 2026.
Alvotech (NASDAQ:ALVO) maintains its outlook for achieving FDA approval for these BLAs within the 2026 calendar year. The company continues to focus on finalizing the necessary data compilation to support the upcoming regulatory submissions.
Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. The firm’s focus is on the development of its product candidates, with its operations divided into the following geographical segments: Europe, North America, Asia, and Other.
While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
